Medication can be one part of alcohol-use disorder treatment, alongside psychological care and continuing support. The choice depends on the treatment goal, withdrawal needs, other medicines, physical health, and the person’s preferences. Swiss product information is particularly important: an option described on an overseas website may have different prescribing conditions, availability, or reimbursement arrangements in Switzerland.
This guide explains the roles of several medicines and the questions to discuss with a Swiss prescriber. It does not provide doses, a self-detox plan, or a recommendation to start, stop, or switch medication. A useful appointment should connect the proposed medicine to a clear goal and an agreed monitoring plan.
Distinguish withdrawal treatment from continuing alcohol treatment
The NIAAA overview of alcohol-use disorder explains that withdrawal can be dangerous and that detoxification alone does not constitute the whole treatment of alcohol-use disorder. Managing an acute withdrawal episode and reducing the likelihood or consequences of future drinking are related but different clinical tasks.
Ask the prescriber which task the medicine is intended to address. A medicine used for continuing treatment should not be assumed to protect against dangerous withdrawal. Describe current drinking, recent changes, previous withdrawal, and any seizures or hospital care. If withdrawal assessment is needed, establish who will arrange it before making a change in use.
Our alcohol withdrawal guide explains the assessment and handoff to ongoing treatment. For immediate medical danger, call 144, as listed in Swiss emergency guidance. A routine medication discussion should not delay urgent assessment.
Acamprosate: a role in maintaining abstinence
The Swiss Campral product information describes acamprosate for maintaining abstinence after withdrawal treatment, in combination with other therapeutic measures. It explicitly states that the medicine is not suitable for treating the withdrawal phase itself. That distinction should be clear in the plan before treatment begins.
The same information identifies kidney impairment as an important contraindication and includes other precautions and population limitations. Ask the prescriber how kidney function, age, pregnancy or breastfeeding, and other health issues affect suitability. The clinician should review the current full product information rather than choosing on the basis of one favorable characteristic.
Discuss how the prescribed regimen would fit into a normal day and what to do if it becomes difficult to follow. Ask for written instructions about missed doses and when to contact the practice. If the goal is abstinence, also identify the psychological and practical support that will accompany medication. The prescription should have a defined role within that wider plan.
Naltrexone: opioid-related questions must be explicit
The Swiss Naltrexin product information describes naltrexone as additional treatment within a comprehensive program, including psychological support, after detoxification. It requires initiation and monitoring by a suitably qualified physician with relevant experience. This is the Swiss product’s stated framework; it should not be replaced by an online dosing strategy from another jurisdiction.
Naltrexone blocks opioid effects. The product information warns about use with opioid-containing medicines or ongoing opioid dependence and the possibility of precipitating severe withdrawal. Liver and kidney health also affect suitability. Tell the prescriber about opioid pain treatment, opioid agonist treatment, recent opioid use, and any planned procedure that may involve analgesia.
Ask how other treating clinicians should be informed. If surgery, dental treatment, or emergency care becomes necessary, the care team needs an accurate medication list. Do not attempt to overcome an opioid-blocking medicine’s effects or alter an established opioid regimen yourself. The prescriber should coordinate any required change with the professionals managing the other condition.
Nalmefene: a specific reduction-focused indication
The Swiss clinical resource Praxis Suchtmedizin’s nalmefene guidance describes a reduction-focused option for selected adults with alcohol dependence, without physical withdrawal symptoms or a need for immediate detoxification. It emphasizes accompanying psychosocial support and assessment by a clinician. This is not a general alternative to medically necessary withdrawal care.
The European Medicines Agency’s Selincro information likewise describes use in selected adults with persistently high-risk drinking after assessment. It states that nalmefene does not prevent alcohol’s intoxicating effects. Opioid use and severe liver or kidney impairment are among the important restrictions described. The EMA information explains the medicine but does not determine Swiss reimbursement.
Ask why a reduction-focused option fits the assessment and what outcome will be reviewed. If the person’s medical circumstances make abstinence the recommended goal, that needs a clear discussion. The existence of a medicine intended to reduce drinking does not mean continued drinking is safe in every situation.
Disulfiram: understanding the alcohol reaction is essential
Praxis Suchtmedizin’s disulfiram information explains that it interferes with alcohol metabolism and can produce an adverse reaction when alcohol is consumed. It describes an abstinence-oriented use requiring informed participation, clinical assessment, and monitoring, rather than a medicine that can be given secretly to make someone stop drinking.
Ask the prescriber and pharmacist to explain alcohol exposure precautions, interactions, adverse effects, and the response to accidental exposure. Do not test the reaction yourself. The clinical resource also discusses medical contraindications and supply concerns; current availability should be checked with the dispensing pharmacy rather than inferred from an older webpage.
If disulfiram is proposed, clarify why it is appropriate compared with other options and how administration and review will be organized. The discussion should address the person’s actual goals and ability to follow the plan. A relative’s wish for certainty is not a substitute for the patient’s informed participation in treatment.
Bring the information that can change the choice
Prepare one current list covering prescribed medicines, nonprescription products, supplements, and substances. Include treatments provided by other clinics and prescriptions from another country. If the exact name is uncertain, bring the packaging or ask the pharmacy to help reconcile the list. Record what is actually taken, not only what appears on an old prescription.
| Information for the prescriber | Why the discussion matters |
|---|---|
| Current drinking and previous withdrawal | Clarifies whether acute medical care is needed before the continuing-treatment plan. |
| Opioids and other medicines | Allows a review of interactions and coordination with existing prescribers. |
| Liver and kidney conditions | Can affect which medicine is suitable and what monitoring is required. |
| Pregnancy, breastfeeding, or plans for pregnancy | Requires an individualized assessment using the relevant product information. |
| Earlier medication experiences | Shows what helped, what caused difficulty, and why treatment ended. |
| The treatment goal | Connects the medicine’s intended role with the person’s clinical plan. |
Ask which investigations are needed before treatment and which need repeating later. Obtain a clear explanation of who will review results and communicate any change. A test is useful when its purpose and follow-up are understood, rather than simply added to an admission package.
Keep psychological care connected to the prescription
NIAAA’s evidence-based treatment overview describes behavioral care and medication as treatment options that can be combined according to need. The Swiss Praxis Suchtmedizin medication overview also places medicines within alcohol treatment rather than presenting them as a complete program on their own.
Ask who will help with the situations in which drinking occurs, the effects on relationships, and the practical demands of change. If one professional prescribes and another provides therapy, agree how relevant updates will be shared. Our relapse-prevention therapy guide explains how those goals can become specific work between appointments.
Agree how benefit and burden will be reviewed
Before starting, describe the intended change and when it will be assessed. Ask which symptoms or adverse effects should prompt earlier contact. Record the name of the responsible prescriber, the follow-up date, and the route for questions between visits. If another clinic is involved, establish who will continue prescriptions while the review is pending.
At follow-up, report both benefit and difficulty. A reduction in craving may be useful even when another part of life remains difficult; an adverse effect may make an otherwise promising regimen unworkable. Ask how the clinician interprets that balance and what options remain. Do not assume that one disappointing experience settles the value of every medication option.
Agree in advance what to do if drinking resumes during treatment. The appropriate response depends on the medicine and the clinical situation, so obtain specific instructions rather than relying on a general rule from another patient’s experience. Tell the team what happened, including any symptoms or missed medication. That information allows the prescriber to reassess safety and the treatment plan without asking you to improvise a change.
Our medication management guide explains how to keep multiple reviews connected. If a medicine is to be stopped or changed, obtain an individualized instruction from the prescriber and confirm what replaces its role in the treatment plan.
Verify the Swiss access and payment arrangements
Ask the prescriber or pharmacist to confirm the exact product, current supply, and the applicable prescribing conditions. Ask the insurer about reimbursement for the intended use, including any authorization or limitation. Product authorization, pharmacy availability, and insurance payment are separate questions; a favorable answer to one does not settle the others.
For someone moving between Swiss treatment and care abroad, arrange the receiving prescriber before discharge. Provide the generic medicine name, treatment purpose, monitoring results, and agreed review plan. The most useful medication choice is one that fits the clinical assessment and can be continued, monitored, and reconsidered through a coherent course of care.